Welcome to our dedicated page for Celularity news (Ticker: CELU), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Celularity Inc. (CELU) is a clinical-stage biotechnology pioneer developing placental-derived cell therapies targeting cancer, immune disorders, and degenerative diseases. This page serves as the definitive source for verified company announcements and research developments.
Access real-time updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated news collection provides investors with essential updates on Celularity's NK cell therapies, CAR T-cell advancements, and biomaterial innovations while maintaining compliance with financial disclosure standards.
Key updates include earnings reports, manufacturing expansions, intellectual property developments, and peer-reviewed research publications. Bookmark this page for structured access to Celularity's progress in creating off-the-shelf cellular therapies and its bio-banking operations.
Celularity (CELU) faces potential delisting from Nasdaq due to two separate issues. First, the company failed to pay required fees of $70,000 under Listing Rule 5250(f), which was subsequently paid in full on April 25, 2025. Second, Nasdaq notified the company on April 16, 2024, about its delinquency in filing the Form 10-K for the year ended December 31, 2024, violating Listing Rule 5250(c)(1).
If Celularity doesn't appeal these determinations, trading of its common stock will be suspended on May 1, 2025. The company must address both compliance issues before a Hearings Panel if it appeals. Celularity states it is actively working on filing the 2024 Form 10-K and expects to complete it imminently.
Celularity (NASDAQ: CELU) welcomes the Centers for Medicare & Medicaid Services (CMS) decision to delay the effective date of a Medicare Local Coverage Determination (LCD) for skin substitute products to January 1, 2026. The LCD, originally published in November 2024, concerns skin substitute grafts and cellular products used to treat diabetic foot ulcers and venous leg ulcers.
The delay follows President Trump's January 2025 executive order freezing regulatory guidance not yet in effect. Initially postponed from February 12, 2025, to April 13, 2025, CMS has now further extended the implementation date. This action, led by CMS Administrator Dr. Mehmet Oz, aims to ensure continued Medicare patient access to critical wound care products while allowing time for comprehensive payment system reform.
Celularity (NASDAQ: CELU) announced a publication in Frontiers in Immunology on April 4, 2025, focusing on the relationship between senescence, Natural Killer (NK) cells, and cancer. The publication explores how aging affects the immune system's fight against cancer and highlights the role of senoablative NK cells in disease progression.
The research emphasizes the importance of maintaining NK cell function for healthy aging and discusses the potential of adoptive NK cell therapy to counter immunosenescence. The company's clinical-stage candidate CYNK-001, a placental-derived allogeneic NK cell therapy, has been studied in over 70 subjects with acceptable safety profiles. The therapy aims to eliminate senescent cells that release toxic cytokines promoting inflammation and malignant transformation, potentially benefiting conditions like age-related frailty and sarcopenia.
Celularity Inc. (Nasdaq: CELU) has received recommendation letters from the FDA Tissue Reference Group confirming that its Natalin and Acelagraft™ wound care products meet criteria to be regulated solely under section 361 of the PHS Act as human cell, tissue and cellular and tissue-based products (HCT/P).
Natalin is a decellularized dehydrated amnion derived tri-layer graft, while Acelagraft™ is a decellularized dehydrated amnion derived bi-layer graft. Both products are indicated for use in partial and full thickness acute and chronic wounds.
According to Nova One Advisor, the global Biological Skin Substitutes market was valued at $347.75 million in 2024 and is projected to grow at a CAGR of 8.83% through 2034, reaching $810.50 million. The chronic wounds segment is expected to grow fastest at 9.13% CAGR, with North America representing 42% of the global market.
Celularity (NASDAQ: CELU) has entered into a Master Services Collaboration Agreement with BlueSphere Bio (BSB) for manufacturing BSB's cell therapy products. This marks Celularity's second such collaboration, showcasing its ability to leverage its cGMP manufacturing infrastructure.
The collaboration will initially focus on producing BSB's novel T cell receptor (TCR) T cell therapies at Celularity's 37,000 square foot Florham Park, NJ facility. The agreement covers all aspects of cell therapy manufacturing, including Chemistry, Manufacturing and Controls (CMC), Quality Assurance, and Quality Control. BSB will maintain oversight of its second cell therapy product for treating Acute Myelogenous Leukemia (AML) in the U.S. and internationally.
The partnership aims to provide BSB with affordable clinical advancement opportunities while maintaining process control, utilizing Celularity's technical capabilities and manufacturing infrastructure.
The MASS Coalition has welcomed President Trump's order to freeze regulatory guidance not yet in effect, including Medicare Local Coverage Determinations (LCDs) for skin substitute products. The freeze extends until at least April 13, 2025, allowing for further evaluation and public comment.
This decision particularly benefits Medicare beneficiaries with diabetic foot ulcers and venous leg ulcers, ensuring continued access to treatments that help prevent sepsis and amputations. The Coalition criticized the previous administration's LCD implementation process, stating it was conducted without proper stakeholder consultation and could create a healthcare crisis for diabetics by causing treatment shortages.
Celularity (Nasdaq: CELU) has successfully regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing of its Q3 2024 10-Q report. The company had faced listing compliance issues due to delayed filings of Q1 and Q2 2024 reports. To address these challenges, Celularity has implemented significant improvements to its financial reporting infrastructure, including engaging EisnerAmper LLP as its independent audit firm and enhancing internal controls. The resolution ensures the company's continued listing on the Nasdaq Capital Market.
Celularity (NASDAQ: CELU) has filed its Q3 2024 Form 10-Q, becoming current with quarterly report filings. The company reported significant growth in financial performance:
- Total net revenues reached $36.1 million for the nine months ended September 30, 2024, up 238.6% from $10.7 million in the same period last year
- Q3 2024 total net revenues were $9.3 million, increasing 145.5% from $3.8 million in Q3 2023
- Product sales showed exceptional growth, reaching $26.2 million for the nine months ended September 30, 2024, a 621.1% increase from $3.6 million in the previous year
The company has addressed its Nasdaq listing compliance issues by filing the Q3 Form 10-Q and is implementing improvements to ensure timely financial disclosures.
Celularity (Nasdaq: CELU) received a notification from Nasdaq on November 21, 2024, stating non-compliance with listing requirements due to delayed filing of Q3 2024 Form 10-Q. The notice doesn't immediately affect the company's stock listing on Nasdaq Capital Market. Celularity must submit a compliance plan by January 20, 2025, and if accepted, has until May 13, 2025, to implement it. The filing delay stems from a backlog related to previous quarterly filings. The company expects to file Q3 Form 10-Q shortly and has implemented improvements to its financial reporting infrastructure.
Celularity (CELU) announced that its strategic partner, Genting Berhad, has broken ground on Fontaine Vitale, a state-of-the-art stem cell and regenerative medicine facility in Bali, Indonesia. The facility will use Celularity's placenta-derived stem cells manufactured in their US facility. Operations are expected to start by late 2026. The Asia Pacific stem cell market is valued at $3.0 billion (2024) with projected growth to $7.2 billion by 2030 at a 16.4% CAGR. Future plans include initiating onsite manufacturing operations under Celularity's technical supervision.